Dr. Trippier joined the Pharmaceutical Sciences faculty in September 2012.
He received his undergraduate degree with first class honors in Chemistry and Toxicology at the University of Hull (UK) undertaking undergraduate research on the design and synthesis of novel Angiotensin-converting enzyme inhibitors.
Dr. Trippier received his Ph.D. in 2007 from the University of Oxford (UK) working on the total and diversity orientated synthesis of bioactive natural products. He completed postdoctoral research at The Welsh School of Pharmacy, Cardiff University (UK) in antiviral and anticancer medicinal chemistry.
He joins the School of Pharmacy from Northwestern University, IL where he conducted research in the laboratory of Richard B. Silverman on the synthesis and intracellular target identification of potential new therapeutics for the treatment of neurodegenerative disease.
Research in the Trippier lab involves the use of state of the art organic and medicinal chemistry techniques combined with chemical biology approaches to design, synthesize and evaluate new molecules for the treatment of human disease and to probe biological systems with a particular emphasis on pediatric diseases.Specific areas of interest include:Design and synthesis of compounds that modulate the tumor-stromal cell interaction as a novel mode of action for the treatment of drug resistant cancers in both adult and pediatric indications. Based on a natural product hit structure we are conducting studies to identify the pharmacophore of this compound to allow optimization of activity, lipophilicity and toxicity properties.Evaluation of small molecule AKR1C3 inhibitors for the treatment of prostate cancer and AML. Based on a natural product hit structure the group is engaged in structure-activity relationship studies to identify the pharmacophore of the compound and enhance both activity and selectivity. We are concurrently investigating the possibility that our compound library may exhibit unique dual-target activity.Discovery of neuroprotective compounds that have the potential to be used to treat neurodegenerative diseases. The group has identified a hit compound active in the pediatric neurodegenerative disease Batten disease. We are working to establish a structure-activity relationship and enhance the efficacy of this compound.We are also engaged on several collaborative projects with other faculty in the School of Pharmacy and wider TTUHSC community in the areas of drug delivery and small molecule inhibitor synthesis.